Skip to main content

Table 2 Changes of parameters of interest pre- and post-medical treatment

From: Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats

Variables Sham Control Low-dose High-dose
Pre-medical treatment (8 weeks of model production, n = 5 each group)
Body weight (g) 254.8 ± 6.6* 286.6 ± 7.0 290.3 ± 8.7 288.5 ± 10.4
TG (mmol/L) 1.15 ± 0.17* 1.79 ± 0.33 1.78 ± 0.32 1.76 ± 0.43
TC (mmol/L) 3.96 ± 0.26* 4.97 ± 0.34 4.96 ± 0.37 4.95 ± 0.45
LDL-C (mmol/L) 2.12 ± 0.24* 2.85 ± 0.31 2.91 ± 0.57 2.89 ± 0.44
HDL-C (mmol/L) 1.07 ± 0.12 1.11 ± 0.04 1.12 ± 0.04 1.10 ± 0.05
FBG (mmol/L) 4.12 ± 0.08* 4.49 ± 0.11 4.51 ± 0.12 4.50 ± 0.08
NO (umol/L) 12.67 ± 1.37* 9.65 ± 1.05 9.26 ± 1.08 9.44 ± 1.02
CRP (mg/L) 2.15 ± 0.42* 6.37 ± 0.55 6.52 ± 0.73 6.46 ± 0.52
MDA (nmol/L) 0.90 ± 0.06* 2.46 ± 0.18 2.57 ± 0.12 2.52 ± 0.19
ADMA (ng/mL) 43.37 ± 6.65* 60.68 ± 10.17 62.22 ± 8.17 62.30 ± 8.22
Post-medical treatment (4 weeks of medical treatment, n = 10 each group)
Body weight (g) 277.3 ± 8.2* 301.2 ± 7.4 299.6 ± 10.3 300.6 ± 10.5
TG (mmol/L) 1.17 ± 0.22* 1.83 ± 0.42 1.67 ± 0.37 1.50 ± 0.29#
TC (mmol/L) 3.98 ± 0.33* 5.00 ± 0.62 4.81 ± 0.56 4.56 ± 0.36#
LDL-C (mmol/L) 2.13 ± 0.23* 2.87 ± 0.36 2.64 ± 0.52 2.43 ± 0.35#
HDL-C (mmol/L) 1.07 ± 0.14 1.10 ± 0.05 1.12 ± 0.03 1.10 ± 0.03
FBG (mmol/L) 4.14 ± 0.07* 4.56 ± 0.13 4.46 ± 0.15 4.41 ± 0.13
NO (umol/L) 12.88 ± 1.56* 9.03 ± 0.68 10.07 ± 0.64 10.85 ± 0.57#
CRP (mg/L) 2.13 ± 0.39* 6.43 ± 0.42 5.87 ± 0.16 5.35 ± 0.66#
MDA (nmol/L) 0.93 ± 0.07* 2.52 ± 0.15 2.29 ± 0.09 2.05 ± 0.07#
ADMA (ng/mL) 44.64 ± 7.08* 62.33 ± 10.08 58.75 ± 8.07 54.46 ± 9.15#
ALT (U/L) 21.43 ± 3.24 26.55 ± 5.21 24.47 ± 6.08 22.39 ± 3.76
AST (U/L) 24.36 ± 6.77 22.55 ± 4.09 21.56 ± 3.35 23.30 ± 6.12
CK (U/L) 18.24 ± 2.23 21.30 ± 2.08 20.07 ± 3.35 20.35 ± 2.56
  1. Denote: *P < 0.05 versus other groups, #P < 0.05 versus control group.